Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
about
Abacavir versus other nucleoside reverse transcriptase inhibitor (NRTI) backbone therapies for treatment of HIV infectionEvaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infectionThe 2015 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected KoreansImpact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*Differential adipose tissue gene expression profiles in abacavir treated patients that may contribute to the understanding of cardiovascular risk: a microarray studyA randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individualsOptimal Treatment Strategies in the Context of 'Treatment for Prevention' against HIV-1 in Resource-Poor SettingsThe Global Health Impact Index: Promoting Global HealthLong-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical PracticeComparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trialChallenges in initiating antiretroviral therapy in 2010.What's new for antiretroviral treatment in women with HIVNoninfectious Diarrhea in HIV Seropositive Individuals: a Review of Prevalence Rates, Etiology, and Management in the Era of Combination Antiretroviral TherapyChanges in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine.Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapySimplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trialAbacavir/lamivudine combination in the treatment of HIV: a review.Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovirEvaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy.Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimensSafety analysis of Epzicom® (lamivudine/abacavir sulfate) in post-marketing surveillance in JapanSafety analysis of Ziagen® (abacavir sulfate) in postmarketing surveillance in JapanDolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.Health needs of HIV-infected women in the United States: insights from the women living positive survey.HIV and HAART-Associated DyslipidemiaCystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial.Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials.Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.Antiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committeeProtease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review.Management of HIV infection in treatment-naive patients: a review of the most current recommendations.Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV.Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.Cost-effectiveness analysis of initial HIV treatment under Italian guidelines.
P2860
Q24235506-9CB48BD6-E1CF-4A7A-B6CB-DC760FD824D4Q26750406-E5A510C9-0598-4678-89A2-2BC1D22D926BQ26781379-FC7CA4B3-9495-4774-8187-2F5661E01B32Q27015850-1042742D-AE0D-44C7-A858-0FC8CCE9401FQ28543075-B5441470-16DC-487A-B791-02AFA6807D12Q28543212-5AEF9265-1336-4297-A21E-F10C1CDABEFDQ28547109-B9722240-FF49-42B7-B92D-ECD0A399450DQ28551476-38E26C61-024E-46E9-9512-4A911CCFFD47Q28554567-757107DB-B72B-472D-84D2-E0FEFA9A9475Q28730855-A5C1B16D-AC48-44F3-9EF4-CDC84E2007E2Q30227046-D5CCF402-9913-4A8D-BB81-62C7F54A7E36Q30391322-9535D7FF-4A74-41C2-9BD1-26B4EE83DC5FQ30609066-99477E35-7B81-4937-BE80-DB68B685F115Q30842348-312B7B3B-231E-4D75-B042-20D2E8FFE78BQ31118978-991E1630-458B-438D-9936-3C5A4F73AD9BQ33565604-A547CD96-F692-4749-8433-37EE6D98F52EQ33604322-A3B27ED4-CC71-4DE3-9B1D-25CF35B7D303Q33715435-D3E46980-111B-44F3-8FBB-DA5190771DEDQ33767281-95A90650-9861-430E-8697-D0A21709C241Q33775397-37403008-05B3-40F8-99D9-177E90939799Q33812049-C1B79137-171E-498A-976F-E214A503DED3Q34039680-3B7ACC11-D1EB-4F89-8D6F-2B52894BE60CQ34126724-5E7EA9F9-8150-4982-ABC7-8B1B0C2437A6Q34134900-B72D621A-61A0-4BAD-A61C-EE7652211CFAQ34488494-187C7CB0-14B1-42D2-A33B-69D34A0A0C33Q34503452-A54A51C5-EB89-4FC3-8533-BB8D8DEB3DD4Q34503521-4616AC09-3984-4199-9DBB-2F3F2E79AEA2Q34823275-5BACE235-689E-46E4-AD8F-03BE9B08F33DQ34904319-2B73C30B-FE58-4265-B893-97F729B69C92Q35020217-A0ED0266-AE21-481F-A134-2B1A28B37A10Q35071954-7D8302C1-8113-4691-9678-37F87C763298Q35109199-1B438DB6-8717-4E61-AF47-C683868BA6D2Q35109483-852D6287-65E7-48C9-AEB8-4DB51A84A43DQ35124959-451A75F7-E073-4274-A3AD-5722EE478FB6Q35186842-CEB67810-CE52-48BA-BF33-C54F8E07BB0FQ35188723-9DD0213C-4CFC-411F-B02A-D678ECF03822Q35214141-32670F84-DFCF-42E3-90B3-98AE910364CBQ35233168-674EB5A8-BCC1-407C-80FB-C6F73D27CD04Q35288691-EE32FC18-B771-4955-A48C-C72BE4394E6FQ35602604-0B445261-D1C8-444B-B4F2-BFD2DDD29611
P2860
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Randomized, double-blind, plac ...... vir for initial HIV treatment.
@en
Randomized, double-blind, plac ...... vir for initial HIV treatment.
@nl
type
label
Randomized, double-blind, plac ...... vir for initial HIV treatment.
@en
Randomized, double-blind, plac ...... vir for initial HIV treatment.
@nl
prefLabel
Randomized, double-blind, plac ...... vir for initial HIV treatment.
@en
Randomized, double-blind, plac ...... vir for initial HIV treatment.
@nl
P2093
P1433
P1476
Randomized, double-blind, plac ...... vir for initial HIV treatment.
@en
P2093
Cindy Vavro
Denise H Sutherland-Phillips
Derek Fine
HEAT Study Team
Kimberly Y Smith
Louis Sloan
Mark S Shaefer
Nicholaos Bellos
Parul Patel
P304
P356
10.1097/QAD.0B013E32832CBCC2
P407
P577
2009-07-01T00:00:00Z